Results 41 to 50 of about 2,198,265 (159)
A phenomap of TTR amyloidosis to aid diagnostic screening
ESC Heart Failure, Volume 12, Issue 2, Page 1113-1118, April 2025.Abstract Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.
Alexios S. Antonopoulos +4 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1326-1335, April 2025.Abstract Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction.
Robin Willixhofer +25 more
wiley +1 more source
Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR‐ACT
, 2021 Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is a progressive, fatal disorder that remains underdiagnosed. The Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) was the first large clinical trial to include both wild‐type (ATTRwt)
Martha Grogan +13 more
core +1 more source
Transthyretin amyloid cardiomyopathy: Treatment pipeline, clinical trials, and challenges
Journal of Public Health and Primary Care, 2021 Transthyretin amyloid cardiomyopathy (ATTR-CM) is potentially a fatal disease characterized by abnormal buildup of amyloid fibrils primarily in the heart causing progressive heart failure. It is categorized into two subtypes-hereditary ATTR and wild type
Sweety Sharma, Bhawna Sharma
doaj +1 more source
A Case of Systemic Amyloidosis Diagnosed After Excision of a Cutaneous Tumour of the Buttocks
JEADV Clinical Practice, EarlyView.ABSTRACT A 72‐year‐old Japanese man was referred to our hospital with two tumours on the buttocks. Two solitary, 2.5 × 1.5 cm‐sized, dark brown, well‐demarcated elevated plaques were observed, one on each side of the gluteal cleft, and dermoscopic examination showed comedo‐like openings, multiple milia‐like cysts, and a cerebriform pattern with ...
Tomomichi Shimizu +9 more
wiley +1 more source
Deep phenotyping of p.(V142I)-associated variant ATTR amyloid cardiomyopathy: distinct from wild-type ATTR amyloidosis? [PDF]
, 2023 Aims: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure. A total of 3–4% of individuals of African descent carry a TTR gene mutation encoding the p.(V142I) variant, a powerful risk factor for development
Porcari, Aldostefano +29 more
core +1 more source
Orphanet Journal of Rare Diseases, 2022 Background Transthyretin cardiac amyloidosis, also known as transthyretin cardiomyopathy (ATTR-CM) is a poorly-recognized disease with delayed diagnosis and poor prognosis.
Suk-Chan Jang +6 more
doaj +1 more source
Pacing and Clinical Electrophysiology, EarlyView.ABSTRACT Atrioventricular conduction disturbances and the need for cardiac implantable electronic device (CIED) therapy are frequently required after transcatheter tricuspid valve implantation (TTVI). The interaction between the annulus, transcatheter heart valve and the leads is often complex and the optimal management under debate.
Thomas Seiler +9 more
wiley +1 more source
Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study. [PDF]
, 2023 Background Tafamidis was approved to treat patients with transthyretin amyloid cardiomyopathy (ATTR-CM) on the basis of findings from the phase 3 Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT).
Witteles, Ronald +8 more
core +1 more source
Scientific ReportsThe diagnosis and awareness of transthyretin amyloidosis cardiomyopathy (ATTR-CM) in heart failure with left ventricular ejection fraction (LVEF) > 40% remains under-recognized.
Se-Eun Kim +6 more
doaj +1 more source